Junya Arima

Dr. Junya Arima

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
HYHirofumi Yoshino
Hirofumi Yoshino
STShuichi Tatarano
Shuichi Tatarano
MTMotoki Tamai
Motoki Tamai
MTMasafumi Tsuruda
Masafumi Tsuruda
SISayaka Iizasa
Sayaka Iizasa
HEHideki Enokida
Hideki Enokida
Exosomes are 40-100 nm nano-sized extracellular vesicles and are receiving increasing attention as novel structures that participate in intracellular communication. We previously found that miRNA-1 (miR-1) functions as a tumor suppressor in renal cell carcinoma (RCC). In this study, we investigated the function of exosomal miR-1 and the possibility that the exosome constitutes a tumor maker in RCC. First, we established the method to collect exosomes from cell lysates and human serum by a spin column-based method. Next, we assessed exosomes using Nanosight nanoparticle tracking analysis and Western blot analysis with exosome marker CD63. We confirmed that exosomes labeled with PKH26 fused with recipient cells. Moreover, miR-1 expression was elevated in RCC cells treated with exosomes derived from miR-1-transfected cells. Functional analyses showed that exosomal miR-1 significantly inhibited cell proliferation, migration and invasion compared to control treatment. Our analyses with TCGA database of RCCs showed that miR-1 expression was significantly downregulated in clinical RCC samples compared to that in normal kidney samples, and patients with low miR-1 expression had poorer overall survival in comparison to patients with high expression. Furthermore, RNA sequence analyses showed that expression levels of several genes were altered by exposure to exosomal miR-1. The analyses with TCGA database indicated that high expression of MYO15A was associated with a poorer outcome in RCC. In addition, RT-qPCR analysis of exosomes from clinical patients' sera showed that MYO15A was significantly upregulated in RCC patients compared to that in healthy controls. This study showed that treatment with exosomal miR-1 might be an effective approach to treating RCCs. In addition, exosomal MYO15A could be a diagnostic tumor marker in RCCs.

Verified
Journal Article
Open access
PDF file
JAJunya Arima
Junya Arima
HYHirofumi Yoshino
Hirofumi Yoshino
WFWataru Fukumoto
Wataru Fukumoto
IKIchiro Kawahara
Ichiro Kawahara
SSSaeki Saito
Saeki Saito
HEHideki Enokida
Hideki Enokida
Bladder cancer (BC) is a common genitourinary malignancy that exhibits silent morbidity and high mortality rates because of a lack of diagnostic markers and limited effective treatments. Here, we evaluated the role of the lncRNA brain cytoplasmic RNA 1 (BCYRN1) in BC. We performed loss-of-function assays to examine the effects of BCYRN1 downregulation in T24 and BOY BC cells. We found that BCYRN1 downregulation significantly inhibited the proliferation, migration, invasion, and three-dimensional spheroid formation ability and induced apoptosis in BC cells. Additionally, gene set enrichment analysis (GSEA) using RNA sequences from tumor fractions showed that BCYRN1 downregulation decreased the expression of mRNAs associated with the cell cycle. These findings were supported by observations of G2/M arrest in flow cytometry assays. Finally, we examined the expression of serum exosomal BCYRN1 as a biomarker. Clinically, BCYRN1 expression in serum exosomes from patients with BC (n = 31) was significantly higher than that in healthy donors (n = 19; mean difference: 4.1-fold higher, p < 0.01). Moreover, in patients who had undergone complete resection of BC, serum exosomal BCYRN1 levels were significantly decreased (n = 8). Thus, serum exosomal BCYRN1 may be a promising diagnostic marker and therapeutic target in patients with BC.

5 August 2025 in Cancer Reports
Verified
Journal Article
Open access
JAJunya Arima
Junya Arima
HYHirofumi Yoshino
Hirofumi Yoshino
STShuichi Tatarano
Shuichi Tatarano
AMAkihiko Mitsuke
Akihiko Mitsuke
YOYoichi Osako
Yoichi Osako
HEHideki Enokida
Hideki Enokida
Background: Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second‐line treatment for urothelial cancer (UC) extends prognosis by only 3 months.Aims: This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.Methods and Results: The study included 44 patients who had recurrence or progression after first‐line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression‐free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).Conclusion: These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.

Verified
Journal Article
Open access
PDF file
SSSaeki Saito
Saeki Saito
HYHirofumi Yoshino
Hirofumi Yoshino
Seiya YokoyamaSeiya Yokoyama
Seiya Yokoyama
MTMitsuhiko Tominaga
Mitsuhiko Tominaga
GLGang Li
Gang Li
HEHideki Enokida
Hideki Enokida
Recently, immune checkpoint inhibitors (ICIs) and cabozantinib, a tyrosine kinase inhibitor (TKI), have been used to treat renal cell carcinoma (RCC); the combination of these agents has become a standard treatment for RCC. TKIs generally target vascular endothelial growth factor. However, cabozantinib is characterized by its targeting of MET. Therefore, cabozantinib can be used as a late-line therapy for TKI-resistant RCC. According to data from The Cancer Genome Atlas (TCGA), heat shock transcription factor 4 (HSF4) expression is higher in RCC tissues than in normal renal tissues. HSF4 binds to the MET promoter in colorectal carcinoma to enhance MET expression and promote tumor progression. However, the functional role of HSF4 in RCC is unclear. We performed loss-of-function assays of HSF4, and our results showed that HSF4 knockdown in RCC cells significantly decreased cell functions. Moreover, MET expression was decreased in HSF4-knockdown cells but elevated in sunitinib-resistant RCC cells. The combination of cabozantinib and HSF4 knockdown reduced cell proliferation in sunitinib-resistant cells more than each monotherapy alone. Furthermore, HSF4 knockdown combined with an ICI showed synergistic suppression of tumor growth in vivo. Overall, our strategy involving HSF4 knockdown may enhance the efficacy of existing therapies, such as cabozantinib and ICIs.

11 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAkihiko Mitsuke
Akihiko Mitsuke
TOTakahiko Ohbo
Takahiko Ohbo
JAJunya Arima
Junya Arima
YOYoichi Osako
Yoichi Osako
TSTakashi Sakaguchi
Takashi Sakaguchi
HHHiroshi Harada
Hiroshi Harada
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution, all patients’ glucose tolerance is evaluated perioperatively by oral glucose tolerance tests (OGTTs) at pre-KT, and 3, 6, and 12 month (mo.) after KT. We analyzed the insulinogenic index (ISI) and homeostasis model assessment beta cell (HOMA-β) based on the immunoreactive insulin (IRI) levels to determine how glucose tolerance changed after KT in 214 patients who had not been diagnosed with DM before KT. In addition, we analyzed the body mass index (BMI) which may also influence glucose tolerance after KT. The concentration of tacrolimus (TAC) in blood was also measured as the area under the curve (AUC) to examine its effects at each sampling point. The preoperative-OGTTs showed that DM was newly diagnosed in 22 of 214 patients (10.3%) who had not been given a diagnosis of DM by the pre-KT fasting blood sugar (FBS) tests. The glucose tolerance was improved in 15 of 22 DM patients at 12 mo. after KT. ISI and IRI deteriorated only at 3 mo. after KT but improved over time. There was a trend of an inverse correlation between HOMA-β and TAC-AUC. We also found inverse correlations between IRI and an increase in BMI from 3 to 12 mo. after KT. Early corticosteroid withdrawal or the steroid minimization protocol with tacrolimus to maintain a low level of diabetogenic tacrolimus and BMI decrease after KT used by our hospital individualizes lifestyle interventions for each patient might contribute to an improvement in post-KT glucose tolerance.

13 November 2026 in IJU Case Reports
Verified
Journal Article
Open access
TSTakashi Sakaguchi
Takashi Sakaguchi
STShuichi Tatarano
Shuichi Tatarano
MKMari Kirishima
Mari Kirishima
JAJunya Arima
Junya Arima
AMAkihiko Mitsuke
Akihiko Mitsuke
HEHideki Enokida
Hideki Enokida
Introduction: A retroperitoneal Müllerian cyst is extremely rare. We report our experience treating an adolescent female who presented with a ruptured retroperitoneal Müllerian cyst. Case Presentation: A 15‐year‐old girl presented with the sudden onset of right lower abdominal pain after coughing. Computed tomography and magnetic resonance imaging revealed a multilocular cystic lesion in the right retroperitoneum with findings suggestive of rupture. Emergency laparoscopic resection was performed given her young age, severe symptoms, the risk of re‐rupture, and the inability to exclude malignancy. The histopathologic examination confirmed a retroperitoneal Müllerian cyst with no evidence of malignancy. Conclusion: Emergency laparoscopic resection enabled a definitive diagnosis and successful treatment of a ruptured retroperitoneal Müllerian cyst.